Regenerative Medical Technology (RMTG) Cash from Operations (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Cash from Operations of 102124.0 for Q1 2026, up 78.82% year-over-year from 57109.0 in Q1 2025, and up 167.37% quarter-over-quarter from 38196.0 in Q4 2025.
Regenerative Medical Technology (RMTG) Cash from Operations (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Cash from Operations history runs 9 years deep, the most recent figure standing at 102124.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 78.82% year-over-year to 102124.0; the TTM figure through Mar 2026 stood at 661504.0 (down 182.7% YoY), while the FY2025 annual figure was 706519.0, down 183.05% from the prior year.
- Cash from Operations for Q1 2026 stood at 102124.0, up from 38196.0 in the prior quarter.
- The five-year high for Cash from Operations was 379393.0 in Q4 2024, with the low at 598093.0 in Q2 2025.
- The 5-year median for Cash from Operations is 6775.0 (2023), against an average of 75707.71.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 2592.27% in 2024, then sank 761.62% in 2025.
- Regenerative Medical Technology's Cash from Operations stood at 49430.0 in 2022, then surged by 40.52% to 29399.0 in 2023, then surged by 1390.5% to 379393.0 in 2024, then plunged by 89.93% to 38196.0 in 2025, then surged by 167.37% to 102124.0 in 2026.
- Business Quant data shows RMTG's Cash from Operations at 102124.0 in Q1 2026, 38196.0 in Q4 2025, and 203731.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 102,124.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,124.00 |
| Mar 31, 2026 | 102,124.00 |
| Dec 31, 2025 | 38,196.00 |
| Dec 31, 2025 | 38,196.00 |
| Sep 30, 2025 | -203,731.00 |
| Sep 30, 2025 | -203,731.00 |
| Jun 30, 2025 | -598,093.00 |
| Jun 30, 2025 | -598,093.00 |
| Mar 31, 2025 | 57,109.00 |
| Mar 31, 2025 | 57,109.00 |
| Dec 31, 2024 | 379,393.00 |
| Dec 31, 2024 | 379,393.00 |
| Sep 30, 2024 | 272,942.00 |
| Sep 30, 2024 | 272,942.00 |
| Jun 30, 2024 | 90,398.00 |
| Jun 30, 2024 | 90,398.00 |
| Mar 31, 2024 | 107,966.00 |
| Mar 31, 2024 | 107,966.00 |
| Dec 31, 2023 | -29,399.00 |
| Dec 31, 2023 | -29,399.00 |